ESMO 2023 | Multiparametric MRI for predicting immunotherapy response in melanomas

Marco Donia, MD, PhD, Copenhagen University Hospital, Herlev, Denmark, outlines how multiparametric MRI (mpMRI) combined with pre-treatment biopsies can predict both clinical outcomes of immunotherapy and some etiological parameters in a Phase I melanoma cohort. He states the future challenge is identifying whether it is possible to identify these etiological agents and use them to help predict treatment outcomes in both heterogeneous cohorts with heterogeneous tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.